Benitec Biopharma ROA 2014-2022 | BNTC

Current and historical return on assets (ROA) values for Benitec Biopharma (BNTC) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
Benitec Biopharma ROA - Return on Assets Historical Data
Date TTM Net Income Total Assets Return on Assets
2022-09-30 $-0.02B $0.02B -150.00%
2022-06-30 $-0.02B $0.01B -150.00%
2022-03-31 $-0.02B $0.01B -107.94%
2021-12-31 $-0.02B $0.01B -109.09%
2021-09-30 $-0.02B $0.02B -94.12%
2021-06-30 $-0.01B $0.02B -94.92%
2021-03-31 $-0.01B $0.01B -104.00%
2020-12-31 $-0.01B $0.02B -118.92%
2020-06-30 $-0.01B $0.01B -85.71%
2020-03-31 $-0.01B $0.00B -62.50%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.006B $0.000B
Benitec Biopharma Limited is a biotechnology company which developed a patented gene silencing technology delivered by gene therapy called DNA directed RNA interference. The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B, drug resistant lung cancer and wet age-related macular degeneration. Benitec Biopharma Limited is based in Sydney, Australia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.293B 9.67
GSK (GSK) United Kingdom $71.300B 9.41
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.249B 19.20
Ginkgo Bioworks Holdings (DNA) United States $3.996B 0.00
Myovant Sciences (MYOV) United Kingdom $2.614B 0.00
Arcus Biosciences (RCUS) United States $1.485B 22.29
Biohaven (BHVN) United States $1.240B 0.00
Emergent Biosolutions (EBS) United States $0.697B 5.48
ADC Therapeutics SA (ADCT) Switzerland $0.356B 0.00
Enzo Biochem (ENZ) United States $0.070B 0.00
Ambrx Biopharma (AMAM) United States $0.070B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.024B 0.00